EP2 Receptor Blocking Peptide

Each vial contains 200 µg of lyophilized peptide derived from the human EP2 receptor sequence (C-terminal amino acids 335-358; SLRTQDATQTSCSTQSDASKQADL).{3178} This peptide was used as an antigen for production of the EP2 receptor polyclonal antibody (Catalog No. 101750) and can be used in conjunction with this antibody to block protein-antibody complex formation during immunochemical analysis for the EP2 receptor. The biological effects of prostaglandin E2 (PGE2) are mediated through interaction with four distinct membrane-bound G-protein coupled EP receptors: EP1, EP2, EP3, and EP4.{1422,6741} Binding of PGE2 to the EP2 receptor results in an increase in adenylate cyclase activity with a subsequent increase in cAMP.{3178,5500} Pharmacologically, EP2 receptors mediate relaxation of smooth muscle and are distinguished from EP4 receptors by their sensitivity to the EP2 receptor selective agonist butaprost.{1422,6741,3178} The human EP2 receptor is comprised of 358 amino acids with a molecular mass of approximately 40,000.{3178} A band at 53 kDa is detected in most samples by western blotting. mRNA for the EP2 receptor is expressed in a variety of tissues including lung, placenta, spleen, intestine, kidney, and sensory neuron.{3178,5500,9050}